Motzer et al.'s CHEKMATE-025 trial showed that irrespective of PD-L1 expression, nivolumab and everolimus improved OS in patients with refractory ccRCC consistently [38]. This evidence concerns the gene CD274 and nonpapillary renal cell carcinoma.